Home › Compare › EEEND vs ABBV

EEEND vs ABBV: Dividend Comparison 2026

EEEND yields 12578.62% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EEEND wins by $530630960824786880.00M in total portfolio value
10 years
EEEND
EEEND
● Live price
12578.62%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$530630960824786880.00M
Annual income
$522,460,281,137,981,670,000,000.00
Full EEEND calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — EEEND vs ABBV

📍 EEEND pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEEENDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EEEND + ABBV cover 4 of 12 months — good coverage

Jan
ABBV
Feb
—
Mar
—
Apr
ABBV
May
—
Jun
—
Jul
ABBV
Aug
—
Sep
—
Oct
ABBV
Nov
—
Dec
—
EEEND pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EEEND
Annual income on $10K today (after 15% tax)
$1,069,182.39/yr
After 10yr DRIP, annual income (after tax)
$444,091,238,967,284,400,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, EEEND beats the other by $444,091,238,967,284,400,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EEEND + ABBV for your $10,000?

EEEND: 50%ABBV: 50%
100% ABBV50/50100% EEEND
Portfolio after 10yr
$265315480412393440.00M
Annual income
$261,230,140,568,990,830,000,000.00/yr
Blended yield
98.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EEEND
No analyst data
Altman Z
44.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EEEND buys
0
ABBV buys
0
No recent congressional trades found for EEEND or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEEENDABBV
Forward yield12578.62% ✓3.67%
Annual dividend / share$2.00$6.20 ✓
Payout ratio50% ✓58%
1-year div growth0%4.7% ✓
5-year div CAGR0%8.9% ✓
Portfolio after 10y$530630960824786880.00M ✓$39.9K
Annual income after 10y$522,460,281,137,981,670,000,000.00 ✓$1,154.43
Total dividends collected$530089142386534400.00M ✓$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EEEND vs ABBV ($10,000, DRIP)

YearEEEND PortfolioEEEND Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,268,562$1,257,861.64$11,520$399.75+$1.26M → EEEND
2$150,485,867$149,128,505.87$13,261$450.98+$150.47M → EEEND
3$16,694,376,373$16,533,356,495.83$15,255$508.41+$16694.36M → EEEND
4$1,732,024,490,841$1,714,161,508,122.03$17,536$572.74+$1732024.47M → EEEND
5$168,061,214,785,330$166,207,948,580,129.47$20,145$644.78+$168061214.77M → EEEND
6$15,252,193,229,276,470$15,072,367,729,456,168.00$23,126$725.38+$15252193229.25M → EEEND
7$1,294,707,312,727,053,800$1,278,387,465,971,728,000.00$26,532$815.52+$1294707312727.03M → EEEND
8$102,804,034,285,858,830,000$101,418,697,461,240,890,000.00$30,420$916.26+$102804034285858.80M → EEEND
9$7,636,149,240,004,887,000,000$7,526,148,923,319,019,000,000.00$34,855$1,028.80+$7636149240004887.00M → EEEND
10$530,630,960,824,786,900,000,000$522,460,281,137,981,670,000,000.00$39,914$1,154.43+$530630960824786880.00M → EEEND

EEEND vs ABBV: Complete Analysis 2026

EEEND — Stock

88 Energy Limited explores for oil and gas properties in the United States. It primarily holds a 75% working interest in the Icewine project, which covers an area of approximately 193,000 acres located in North Slope of Alaska, the United States; 100% working interest in the Yukon project covering an area of approximately 38,681 acres situated in the Central North Slope of Alaska; 50% working interest in Peregrine project covering an area of approximately 195,373 acres located in the NPR-A region of the North Slope of Alaska; and 100% working interest in the Umiat Oil Field project covering an area of approximately 17,633 acres situated in the immediate south of Peregrine project North Slope of Alaska. The company was formerly known as Tangiers Petroleum Limited and changed its name to 88 Energy Limited in February 2015. 88 Energy Limited was incorporated in 1996 and is based in Subiaco, Australia.

Full EEEND Calculator →

ABBV — Healthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this EEEND vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EEEND vs SCHDEEEND vs JEPIEEEND vs OEEEND vs KOEEEND vs MAINEEEND vs JNJEEEND vs MRKEEEND vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.